![[14C]UAI-101을 수컷 랫드에 단회 경구 투여한 후 뇨와 변에서의 방사능물질의 배설 결과](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_205_table_220.png "[14C]UAI-101을 수컷 랫드에 단회 경구 투여한 후 뇨와 변에서의 방사능물질의 배설 결과")
![담관에 삽관한(Bile-duct cannulated animal) 수컷 랫드에 [14C]UAI-101을 단회 경구 투여한 후 담즙에서의 방사능물질 배설결과](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_206_table_1.png "담관에 삽관한(Bile-duct cannulated animal) 수컷 랫드에 [14C]UAI-101을 단회 경구 투여한 후 담즙에서의 방사능물질 배설결과")
![Inhibitory effect of UAI-101 (1-500 μM) on the uptake of 50 nM [3H]MPP+,a representative substrate for OCT1 and OCT2, in HEK293 cells overexpressing OCT1 and OCT2 (Corning TransportoCells OCT1 and OCT2).](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_225_image_1.png "Inhibitory effect of UAI-101 (1-500 μM) on the uptake of 50 nM [3H]MPP+,a representative substrate for OCT1 and OCT2, in HEK293 cells overexpressing OCT1 and OCT2 (Corning TransportoCells OCT1 and OCT2).")
![Inhibitory effect of UAI-101 (1-500 μM) on the uptake of on the uptake of 0.5 μM [3H]para-aminohippuricacid(PAH), a substrate for OAT1 in HEK293 cells overexpressing OAT1 (Corning TransportoCellsOAT1).](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_225_image_2.png "Inhibitory effect of UAI-101 (1-500 μM) on the uptake of on the uptake of 0.5 μM [3H]para-aminohippuricacid(PAH), a substrate for OAT1 in HEK293 cells overexpressing OAT1 (Corning TransportoCellsOAT1).")
![Inhibitory effect of UAI-101 (1-500 μM) on the uptake of on the uptake of 50 nM [3H]ES, a substrate for OAT3 , in HEK293 cells overexpressing OAT3 (Corning TransportoCellsOAT3).](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_226_image_1.png "Inhibitory effect of UAI-101 (1-500 μM) on the uptake of on the uptake of 50 nM [3H]ES, a substrate for OAT3 , in HEK293 cells overexpressing OAT3 (Corning TransportoCellsOAT3).")
![Inhibitory effects of UAI-101 (1-500 μM) on the uptake of 50 nM [3H]estrone-3-sulfate(ES), a substrate for OATP1B1 in HEK293 cells overexpressing OATP1B1 (Corning TransportoCellsOATP1B1).](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_226_image_2.png "Inhibitory effects of UAI-101 (1-500 μM) on the uptake of 50 nM [3H]estrone-3-sulfate(ES), a substrate for OATP1B1 in HEK293 cells overexpressing OATP1B1 (Corning TransportoCellsOATP1B1).")
![Inhibitory effects of UAI-101 (1-500 μM) on the uptake of 50 nM [3H]estradiol-17b-D-glucuronide (EG), a substrate for OATP1B3, in HEK293 cells overexpressing OATP1B3 (Corning TransportoCells OATP1B3).](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_227_image_1.png "Inhibitory effects of UAI-101 (1-500 μM) on the uptake of 50 nM [3H]estradiol-17b-D-glucuronide (EG), a substrate for OATP1B3, in HEK293 cells overexpressing OATP1B3 (Corning TransportoCells OATP1B3).")
![Inhibitory effect of UAI-101 on the transport activities of P-gp. Inhibitory effect of UAI-101 (5-200 μM) on the B to A transport of 100 nM [3H]digoxin,a representative substrate for p-glycoprotein, was measured in LLC-PK1-MDR1 cells overexpressing P-gp.](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_228_image_1.png "Inhibitory effect of UAI-101 on the transport activities of P-gp. Inhibitory effect of UAI-101 (5-200 μM) on the B to A transport of 100 nM [3H]digoxin,a representative substrate for p-glycoprotein, was measured in LLC-PK1-MDR1 cells overexpressing P-gp.")
![Inhibitory effect of UAI-101 on the transport activities of BCRP. Inhibitory effect of UAI-101 (5-200 μM) on the B to A transport of 50 nM [3H]ES,a representative substrate for BCRP, in LLC-PK1-BCRP cells overexpressing BCRP](https://nrms.kisti.re.kr/bitextimages/TRKO201700010075/TRKO201700010075_228_image_2.png "Inhibitory effect of UAI-101 on the transport activities of BCRP. Inhibitory effect of UAI-101 (5-200 μM) on the B to A transport of 50 nM [3H]ES,a representative substrate for BCRP, in LLC-PK1-BCRP cells overexpressing BCRP")
선택한 단어 수는 입니다.
최소 단어 이상 선택하여야 합니다.
최소 단어 이상 선택하여야 합니다.
선택한 단어 수는 30입니다.
최대 10 단어까지만 선택 가능합니다.
최대 10 단어까지만 선택 가능합니다.
| 주관연구기관 | 안국약품(주) |
|---|---|
| 연구책임자 | 김성천 |
| 참여연구자 | 안순길 |
| 보고서유형 | 5단계보고서 |
| 발행국가 | 대한민국 |
| 언어 | 한국어 |
| 발행년월 | 2015-11 |
| 과제시작연도 | 2014 |
| 주관부처 | 교육과학기술부 Ministry of Education and Science Technology(MEST) |
| 등록번호 | TRKO201700010075 |
| 과제고유번호 | 1711018994 |
| 사업명 | 바이오·의료기술개발 |
| DB 구축일자 | 2017-11-13 |
| 키워드 | 경구용 당뇨치료제.전임상 연구.분자설계.IND 신청.11β-HSD1.oral antidiabetes.preclinical study.molecular modeling.IND application. |
| DOI | https://doi.org/10.23000/TRKO201700010075 |
※ AI-Helper는 부적절한 답변을 할 수 있습니다.